Xiansheng Pharmaceutical on Aug. 20 said it has struck a strategic cooperation with Ruiyang (Shandong) Biopharmaceutical on the domestic Class-1 biologic new drug Kulaivebai mAb injection. Under the deal Xiansheng will hold exclusive commercialization rights in Greater China. The marketing authorisation application has been accepted by the National Medical Products Administration’s Center for Drug Evaluation (CDE) and placed in priority review. The company said the collaboration will strengthen

Israeli forces carried out raids across the West Bank and Jerusalem on the 19th, detaining at least 31 Palestinians, Palestinian sources said. Among those arrested was Palestinian Authority Jerusalem affairs minister Ashraf al-Awar, seized at his home in the Silwan neighborhood south of the Al-Aqsa Mosque in the Old City. Al-Awar was barred from entering the West Bank in January, the PA said, calling the arrest the latest in a series of restrictions on Palestinian officials in Jerusalem. The Israeli military had not commented.

Nebius said it will issue $4.5 billion of convertible bonds to support AI business development; shares fell 6%.